Burrage Capital Management’s Aimmune Therapeutics AIMT Stock Holding History

Burrage Capital Management’s Portfolio AIMT Stock Details AIMT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-332,546	Closed	-$11.5M	–	33
2020 Q3	$11.5M	Hold	332,546	–	–	9.04%	2
2020 Q2	$5.56M	Buy	332,546 +220,000	+195%	+$3.74M	3.89%	11
2020 Q1	$1.61M	Buy	+112,546	New	+$2.88M	1.58%	23

Burrage Capital Management's AIMT Position: Q4 2020 in Review

Burrage Capital Management sold out of Aimmune Therapeutics (AIMT) in Q4 2020, closing a stake of 332,546 shares — an estimated $11.5M sold.

Burrage Capital Management first reported a position in AIMT in Q1 2020 and held it in 3 quarters. The position peaked at $11.5M in Q3 2020. 0 funds tracked by Wall St. Rank hold AIMT as of Q4 2020.

Burrage Capital Management reported no remaining Aimmune Therapeutics position as of Q4 2020 after selling out during the quarter.
Burrage Capital Management sold 332,546 Aimmune Therapeutics shares in Q4 2020, an estimated $11.5M.
Burrage Capital Management first reported a position in Aimmune Therapeutics in Q1 2020 and held it in 3 quarters.
Burrage Capital Management's Aimmune Therapeutics position peaked at $11.5M in Q3 2020.
0 funds tracked by Wall St. Rank held Aimmune Therapeutics as of Q4 2020.

Based on Burrage Capital Management's 13F filing for Q4 2020, filed 12 Feb 2021.